BACKGROUND: Haptoglobin (Hp) is an abundant serum protein which binds extracorpuscular hemoglobin (Hb). Two alleles exist in humans for the Hp gene, denoted 1 and 2. Diabetic individuals with the Hp 2-2 genotype are at increased risk of developing vascular complications including heart attack, stroke, and kidney disease. Recent evidence shows that treatment with vitamin E can reduce the risk of diabetic vascular complications by as much as 50% in Hp 2-2 individuals. We sought to develop a rapid and accurate test for Hp phenotype (which is 100% concordant with the three major Hp genotypes) to facilitate widespread diagnostic testing as well as prospective clinical trials. METHODS: A monoclonal antibody raised against human Hp was shown to distinguish between the three Hp phenotypes in an enzyme linked immunosorbent assay (ELISA). Hp phenotypes obtained in over 8000 patient samples using this ELISA method were compared with those obtained by polyacrylamide gel electrophoresis or the TaqMan PCR method. RESULTS: Our analysis showed that the sensitivity and specificity of the ELISA test for Hp 2-2 phenotype is 99.0% and 98.1%, respectively. The positive predictive value and the negative predictive value for Hp 2-2 phenotype is 97.5% and 99.3%, respectively. Similar results were obtained for Hp 2-1 and Hp 1-1 phenotypes. In addition, the ELISA was determined to be more sensitive and specific than the TaqMan method. CONCLUSIONS: The Hp ELISA represents a user-friendly, rapid and highly accurate diagnostic tool for determining Hp phenotypes. This test will greatly facilitate the typing of thousands of samples in ongoing clinical studies.
BACKGROUND:Haptoglobin (Hp) is an abundant serum protein which binds extracorpuscular hemoglobin (Hb). Two alleles exist in humans for the Hp gene, denoted 1 and 2. Diabetic individuals with the Hp 2-2 genotype are at increased risk of developing vascular complications including heart attack, stroke, and kidney disease. Recent evidence shows that treatment with vitamin E can reduce the risk of diabetic vascular complications by as much as 50% in Hp 2-2 individuals. We sought to develop a rapid and accurate test for Hp phenotype (which is 100% concordant with the three major Hp genotypes) to facilitate widespread diagnostic testing as well as prospective clinical trials. METHODS: A monoclonal antibody raised against human Hp was shown to distinguish between the three Hp phenotypes in an enzyme linked immunosorbent assay (ELISA). Hp phenotypes obtained in over 8000 patient samples using this ELISA method were compared with those obtained by polyacrylamide gel electrophoresis or the TaqMan PCR method. RESULTS: Our analysis showed that the sensitivity and specificity of the ELISA test for Hp 2-2 phenotype is 99.0% and 98.1%, respectively. The positive predictive value and the negative predictive value for Hp 2-2 phenotype is 97.5% and 99.3%, respectively. Similar results were obtained for Hp 2-1 and Hp 1-1 phenotypes. In addition, the ELISA was determined to be more sensitive and specific than the TaqMan method. CONCLUSIONS: The Hp ELISA represents a user-friendly, rapid and highly accurate diagnostic tool for determining Hp phenotypes. This test will greatly facilitate the typing of thousands of samples in ongoing clinical studies.
Authors: I-Min Lee; Nancy R Cook; J Michael Gaziano; David Gordon; Paul M Ridker; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: Edgar R Miller; Roberto Pastor-Barriuso; Darshan Dalal; Rudolph A Riemersma; Lawrence J Appel; Eliseo Guallar Journal: Ann Intern Med Date: 2004-11-10 Impact factor: 25.391
Authors: M Schnaider Beeri; U Goldbourt; J M Silverman; S Noy; J Schmeidler; R Ravona-Springer; A Sverdlick; M Davidson Journal: Neurology Date: 2004-11-23 Impact factor: 9.910
Authors: Dana Dabelea; Gregory Kinney; Janet K Snell-Bergeon; John E Hokanson; Robert H Eckel; James Ehrlich; Satish Garg; Richard F Hamman; Marian Rewers Journal: Diabetes Date: 2003-11 Impact factor: 9.461
Authors: Rabea Asleh; Stuart Marsh; Mark Shilkrut; Ofer Binah; Julia Guetta; Flavio Lejbkowicz; Ben Enav; Naim Shehadeh; Yoram Kanter; Orit Lache; Osher Cohen; Nina S Levy; Andrew P Levy Journal: Circ Res Date: 2003-05-15 Impact factor: 17.367
Authors: Tina Costacou; Andrew P Levy; Rachel G Miller; Janet Snell-Bergeon; Rabea Asleh; Dan Farbstein; Catherine E Fickley; Georgia Pambianco; Rona de la Vega; Rhobert W Evans; Trevor J Orchard Journal: Acta Diabetol Date: 2015-05-24 Impact factor: 4.280
Authors: Resham L Gurung; M Yiamunaa; Sylvia Liu; Jian Jun Liu; Clara Chan; Robin Wai Munn Choo; Keven Ang; Chee Fang Sum; Subramaniam Tavintharan; Su Chi Lim Journal: Cardiovasc Diabetol Date: 2019-05-30 Impact factor: 9.951
Authors: Trevor J Orchard; Wanjie Sun; Patricia A Cleary; Saul M Genuth; John M Lachin; Paula McGee; Andrew D Paterson; Philip Raskin; Yefim Anbinder; Andrew P Levy Journal: Diabetes Date: 2013-06-12 Impact factor: 9.461
Authors: Tina Costacou; Caterina Rosano; Howard Aizenstein; Joseph M Mettenburg; Karen Nunley; Robert E Ferrell; Trevor J Orchard Journal: Diabetes Date: 2014-09-11 Impact factor: 9.461
Authors: Isidor Minović; Michele F Eisenga; Ineke J Riphagen; Else van den Berg; Jenny Kootstra-Ros; Anne-Roos S Frenay; Harry van Goor; Gerald Rimbach; Tuba Esatbeyoglu; Andy P Levy; Carlo A J M Gaillard; Johanna M Geleijnse; Manfred L Eggersdorfer; Gerjan J Navis; Ido P Kema; Stephan J L Bakker Journal: Sci Rep Date: 2017-10-27 Impact factor: 4.379
Authors: Michal S Beeri; Hung-Mo Lin; Mary Sano; Ramit Ravona-Springer; Xiaoyu Liu; Barbara B Bendlin; Carey E Gleason; Elizabeth Guerrero-Berroa; Laili Soleimani; Lenore J Launer; Scott Ehrenberg; Orit Lache; Yaakov K Seligman; Andrew P Levy Journal: JAMA Netw Open Date: 2018-11-02